Cellectar Biosciences Beheer

Beheer criteriumcontroles 2/4

Cellectar Biosciences' CEO is Jim Caruso, appointed in Jun 2015, has a tenure of 9.42 years. total yearly compensation is $1.97M, comprised of 30.5% salary and 69.5% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth €92.20K. The average tenure of the management team and the board of directors is 2.8 years and 8.5 years respectively.

Belangrijke informatie

Jim Caruso

Algemeen directeur

US$2.0m

Totale compensatie

Percentage CEO-salaris	30.5%
Dienstverband CEO	9.4yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	8.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jim Caruso's beloning veranderd ten opzichte van Cellectar Biosciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$48m
Mar 31 2024	n/a	n/a	-US$57m
Dec 31 2023	US$2m	US$600k	-US$38m
Sep 30 2023	n/a	n/a	-US$38m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$1m	US$569k	-US$29m
Sep 30 2022	n/a	n/a	-US$27m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$2m	US$523k	-US$24m
Sep 30 2021	n/a	n/a	-US$22m
Jun 30 2021	n/a	n/a	-US$20m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$1m	US$475k	-US$15m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$934k	US$451k	-US$14m
Sep 30 2019	n/a	n/a	-US$15m
Jun 30 2019	n/a	n/a	-US$16m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$770k	US$425k	-US$15m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$16m
Dec 31 2017	US$994k	US$410k	-US$15m

Compensatie versus markt: Jim's total compensation ($USD1.97M) is above average for companies of similar size in the German market ($USD488.36K).

Compensatie versus inkomsten: Jim's compensation has increased whilst the company is unprofitable.

CEO

Jim Caruso (65 yo)

9.4yrs

Tenure

US$1,965,140

Compensatie

Mr. James V. Caruso, also known as Jim, is Member of Advisory Board & Director of Hip Innovation Technology, LLC. Mr. Caruso has been the Chief Executive Officer and President of Cellectar Biosciences, Inc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
James Caruso	President	9.4yrs	US$1.97m	0.14% € 92.2k
Chad Kolean	VP, CFO & Secretary	2.8yrs	US$1.11m	0.12% € 79.8k
Jarrod Longcor	Chief Operating Officer	2.8yrs	US$1.36m	0.15% € 99.6k
Darrell Lea	Chief Commercial Officer	2yrs	geen gegevens	0.11% € 74.2k
Andrei Shustov	Senior Vice President of Medical	1.8yrs	geen gegevens	0.15% € 103.1k

2.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: NV4's management team is considered experienced (2.8 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
James Caruso	President	9.4yrs	US$1.97m	0.14% € 92.2k
John Neis	Independent Director	16.8yrs	US$93.25k	0.017% € 11.7k
Frederick Driscoll	Independent Director	7.6yrs	US$93.25k	0.0054% € 3.6k
Stefan Loren	Independent Director	9.4yrs	US$93.25k	0% € 0
Douglas Swirsky	Independent Chairman of the Board	7.6yrs	US$109.88k	0.0070% € 4.7k
Asher Chanan-Khan	Independent Director	3.4yrs	US$48.25k	0% € 0

8.5yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: NV4's board of directors are considered experienced (8.5 years average tenure).

Cellectar Biosciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

Cellectar Biosciences, Inc. Announces Appointment of Shane Lea as Chief Commercial Officer

Cellectar Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Cellectar Biosciences Appoints Jarrod Longcor as Chief Operating Officer

Recent updates

Cellectar Biosciences Regains Compliance with Nasdaq Listing Rule 5250(c)(1) Regarding Filing of Form 10-Q

Cellectar Biosciences Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Cellectar Biosciences, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Cellectar Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Cellectar Biosciences, Inc. Announces Positive Results Data from its Ongoing CLover WaM Pivotal Study Evaluating Iopofosine I 131 for the Treatment of Relapsed/Refractory Waldenstrom's Macroglobulinemia

New major risk - Share price stability

Insufficient new directors

Cellectar Biosciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

New minor risk - Market cap size

New major risk - Financial position

No longer forecast to breakeven

Cellectar Biosciences, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

New major risk - Shareholder dilution

Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study

Cellectar Biosciences, Inc. Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

Forecast to breakeven in 2026

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

Forecast to breakeven in 2026

New minor risk - Profitability

Cellectar Biosciences, Inc. announced that it has received $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc.

New major risk - Financial position

Nasdaq Grants Cellectar Biosciences an Extension to Take Action to Evidence Compliance with Nasdaq Listing Rule 5550(b), on or Before January 4, 2024

Cellectar Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia

New minor risk - Profitability

Cellectar Biosciences, Inc. announced that it expects to receive $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc. and other investors

Cellectar Biosciences Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

New major risk - Share price stability

Cellectar Biosciences, Inc. Provides an Update for Its iopofosine I 131 Clinical Program and Guidance Related to Its Proprietary Phospholipidether Drug Conjugate Platform

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

Cellectar Biosciences, Inc. Announces Appointment of Shane Lea as Chief Commercial Officer

Cellectar Biosciences, Inc. Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

Cellectar Biosciences, Inc. Announces Resolution of Breach of Contract and Intellectual Property Dispute

Cellectar Biosciences, Inc. announced that it has received $3.911327 million in funding

Cellectar Biosciences, Inc. Wins $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

Cellectar Biosciences, Inc. Announces Publication of Data from its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal

Nasdaq Grants Extension to Cellectar Biosciences Until October 31, 2022 to Regain Compliance

Cellectar Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Cellectar Biosciences Appoints Jarrod Longcor as Chief Operating Officer

Cellectar Biosciences, Inc. Presents Data from Its Ongoing Phase 2 Clover-1 Study of Iopofosine I-131 At the 63rd Ash Annual Meeting and Exposition

Cellectar Biosciences, Inc. Announces the Completion of the Part A Portion of A Safety and Tolerability Study of Iopofosine I-131 (Iopofosine) in Combination with External Beam Radiation (Ebrt) in Relapsed or Refractory Head and Neck Cancer

High number of new directors

Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster At the 2021 American Society of Clinical Oncology Annual Meeting

Cellectar Biosciences, Inc. Receives Notification of Formal Grant of the Patent Titled Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles by the Eurasian, Australian and Mexican Patent Authorities

Cellectar Biosciences, Inc. Announces Japan Patent Office Granted Patent, Titled, 'Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles'

New 90-day low: €1.40

Cellectar Biosciences, Inc. Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia

Cellectar Biosciences, Inc. announced that it has received $20.5065 million in funding

Cellectar Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $24.499984 million.

Cellectar Biosciences, Inc. announced that it expects to receive $20.5 million in funding

New 90-day high: €2.10

New 90-day high: €1.51

Cellectar Biosciences, Inc. Announces CLR 131 Has Demonstrated Preliminary Activity in Inoperable Brain Tumors in Phase 1 Study

New 90-day low - €0.94

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd